Clinical trials: Patients with Advanced Solid Tumors
Solid Tumors
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
This is a study of dalotuzumab given as monotherapy and in combination with ridaforolimus for pediatric participants with advanced solid tumors. This study will have three parts.
- Trial name
- NCT01431547
- Testing
- dalotuzumab, ridaforolimus
- Volunteers
- 21 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
First-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), safety and tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of Theliatinib .
- Trial name
- NCT02601248
- Testing
- Theliatinib
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hutchison Medipharma Limited
Solid Tumour
A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours
This study is a trial of Dexanabinol in patients with advanced solid tumours. The purposes of this protocol are to study different doses of the study drug to determine the maximum safe dose and to further understand the safety of…
- Trial name
- NCT01489826
- Testing
- Dexanabinol, Cremophor
- Where
- 3 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- e-Therapeutics PLC
Advanced Solid Tumours
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
This is a Phase I/II study for patients with solid tumors and renal cell carcinoma (RCC; for the Phase II part). L19-IL2 is a tumor targeted immunocytokine constituted of a single chain Fragment variable (scFv) format directed…
- Trial name
- NCT01058538
- Testing
- L19IL2
- Where
- 2 sites in Germany, Italy
- Volunteers
- 33 people
- Sponsor
- Philogen S.p.A.
Tumors
A Study of IMC-A12 in Advanced Solid Tumors
In this study, participants will initially receive intravenous (IV) cixutumumab (IMC-A12) every 2 weeks or every 3 weeks for 6 weeks (one cycle).
- Trial name
- NCT01007032
- Testing
- Cixutumumab
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
Solid Tumor
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Open-label, multicenter, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study.
- Trial name
- PEG (NCT00834704)
- Testing
- PEGPH20
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Halozyme Therapeutics
Neoplasms, Cancer
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor
- Conditions
- Neoplasms, Cancer, Tumors
- Trial name
- NCT01030055
- Testing
- TKI258 (dovitinib)
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Neoplasm Metastasis
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
- Trial name
- NCT00582985
- Testing
- TRC105 chimeric anti-CD105 antibody
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Advanced Solid Tumor, Esophageal Cancer
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with…
- Conditions
- Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers
- Trial name
- NCT06682806
- Testing
- PRT3789, pembrolizumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 6 people
- Sponsor
- Prelude Therapeutics Incorporated
Solid Tumor, Adult, Advanced Solid Tumors
IMX-110 in Patients With Advanced Solid Tumors
Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110.
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumors, Pancreatic Cancer, Breast Cancer
- Trial name
- NCT03382340
- Testing
- Imx-110
- Where
- 2 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Immix Biopharma Australia Pty Ltd
Advanced Refractory Solid Tumors
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Clinical study of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity of oral PI3K/mTOR inhibitor P7170 in…
- Trial name
- NCT01762410
- Testing
- P7170
- Where
- 4 sites in United States, India
- Volunteers
- 60 people
- Sponsor
- Piramal Enterprises Limited
Advanced Solid Tumors, Hematologic Neoplasms
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with…
- Conditions
- Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors
- Trial name
- NCT03219268
- Testing
- tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg
- Where
- 40 sites in United States, Australia and 6 more
- Volunteers
- 277 people
- Sponsor
- MacroGenics
Solid Tumor
Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced…
- Trial name
- NCT06667960
- Testing
- JK06
- Where
- 14 sites in Belgium, Spain
- Volunteers
- 255 people
- Sponsor
- Salubris Biotherapeutics Inc
Advanced Solid Tumors
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
this is a single-arm, open phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacokinetics, and preliminary efficacy of FS-8002 and combination therapy in patients with advanced solid tumors
- Trial name
- NCT06832982
- Testing
- FS-8002 injection, Toripalimab Injection, Chemotherapy
- Where
- 10 sites in China
- Volunteers
- 66 people
- Sponsor
- Shanghai Pushi Medical Science Co. Ltd
Cancer
A Study of ARQ 171 in Patients With Advanced Solid Tumors
This is an open label, dose escalation study of ARQ 171 administered via intravenous infusion (IVI) into a peripheral vein weekly.
- Trial name
- NCT00398840
- Testing
- ARQ 171
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Neoplasms
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
This study is a phase I, open-label, dose escalation trial to determine the maximum tolerated dose (MTD) of a new drug BI 836845 which blocks the insulin growth factor (IGF) pathway believed to be involved in cancer growth.
- Trial name
- NCT01317420
- Testing
- BI 836845
- Where
- 2 sites in United Kingdom
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Cancer
DXP-106 in Solid Tumor Patients.
The goal of this clinical trial is to evaluate the safety and tolerability of DXP-106 in Chinese patients with advanced solid tumors. The main questions it aims to answer are: For Part I: 1.
- Trial name
- DXP-106 (NCT07532018)
- Testing
- DXP-106
- Where
- 4 sites in China
- Volunteers
- 54 people
- Sponsor
- Singlomics Biopharmaceuticals Zhuhai Co., Ltd.
Advanced Cancer, Solid Tumor
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912.
- Conditions
- Advanced Cancer, Solid Tumor, Metastatic Cancer
- Trial name
- NCT06190886
- Testing
- PTX-912
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Proviva Therapeutics, Inc.
Advanced Solid Tumor, Solid Tumor
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors.
- Trial name
- NCT05981703
- Testing
- BGB-26808, Tislelizumab, Chemotherapy
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 337 people
- Sponsor
- BeOne Medicines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.